Akèy › Limfom Difize Gwo Selil B › Oklahoma
Etid klinik pou Limfom Difize Gwo Selil B nan Oklahoma
5 etid pou Limfom Difize Gwo Selil B ap chèche patisipan nan sit nan Oklahoma.
Vil nan Oklahoma
Tèks ofisyèl etid la (Anglè)
Testing the Combination of Anti-cancer Drugs Mosunetuzumab, Polatuzumab Vedotin, and Lenalidomide for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma
- University of Oklahoma Health Sciences Center, Oklahoma City
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Jul 9, 2026 · NCT06015880Acalabrutinib Maintenance for the Treatment of Patients With Large B-cell Lymphoma
- University of Oklahoma, Oklahoma City
Ap rekriteFaz 1/2
Laj 18 a 70 · Tout sèks · Mizajou Mar 10, 2026 · NCT05256641Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
- University of Oklahoma Health Sciences Center, Oklahoma City
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Feb 2, 2026 · NCT05633615Study Adding Drugs to Usual Treatment for Large B-Cell Lymphoma That Returned or Did Not Respond to Treatment
- University of Oklahoma Health Sciences Center, Oklahoma City
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Oct 20, 2025 · NCT05890352A Study of NX-1607 in Adults With Advanced Malignancies
- University of Oklahoma, Oklahoma City
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Sep 9, 2025 · NCT05107674Sous ClinicalTrials.gov, done yo ranmase Oct 1, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.